Decay-Accelerating Factor Expression Modulates the Severity of Experimental Focal Segmental Glomerulosclerosis.

Sofia Bin,Kelly Budge,Micaela Gentile,Manuel Alfredo Podestà, Yaseen Khan,Jamil R Azzi,Luis Sanchez Russo,Gaetano La Manna,Paolo Cravedi

Kidney360（2023）

引用 2|浏览28

暂无评分

摘要

Key PointsGenetically induced decay-accelerating factor (DAF) overexpression prevents adriamycin (ADR)-induced focal segmental glomerulosclerosis (FSGS) in mice.Pharmacologic inhibition of DAF cleavage reduces complement activation in the glomeruli and albuminuria in murine ADR-induced FSGS.Inhibition of complement activation represents a valuable therapeutic strategy for FSGS and, potentially, other glomerular diseases.

查看译文

关键词

glomerular and tubulointerstitial diseases, adriamycin, basic science, C3, C3aR, CD55 antigens, complement, DAF, focal segmental glomerulosclerosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要